Charles Schwab Investment Management Inc Verrica Pharmaceuticals Inc. Transaction History

Charles Schwab Investment Management Inc

$429 Billion
Q1 2024

A detailed history of Charles Schwab Investment Management Inc transactions in Verrica Pharmaceuticals Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 55,356 shares of VRCA stock, worth $403,545. This represents 0.0% of its overall portfolio holdings.

Number of Shares

55,356

Previous 55,356 -0.0%

Holding current value

$403,545

Previous $405,000 19.26%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 09, 2023	BUY	$5.32 - $6.79 $294,493 - $375,867	55,356 New	55,356 $319,000
Q3 2022 Nov 14, 2022	BUY	$2.17 - $4.3 $27,281 - $54,059	12,572 New	12,572 $37,000
Q2 2022 Aug 15, 2022	SELL	$1.81 - $8.93 $60,544 - $298,708	-33,450 Closed	0 $0
Q3 2021 Nov 16, 2021	BUY	$9.55 - $13.96 $22,280 - $32,568	2,333 Added 7.5%	33,450 $419,000
Q1 2021 May 17, 2021	SELL	$10.51 - $17.46 $5,412 - $8,991	-515 Reduced 1.63%	31,117 $472,000

Q4 2020 Feb 16, 2021	BUY	$7.41 - $12.63 $1,244 - $2,121	168 Added 0.53%	31,632 $365,000
Q3 2020 Nov 13, 2020	SELL	$6.16 - $10.3 $14,303 - $23,916	-2,322 Reduced 6.87%	31,464 $244,000
Q1 2020 May 15, 2020	BUY	$7.14 - $16.86 $35,321 - $83,406	4,947 Added 17.15%	33,786 $370,000
Q4 2019 Feb 07, 2020	SELL	$13.08 - $17.43 $66,302 - $88,352	-5,069 Reduced 14.95%	28,839 $459,000
Q3 2019 Nov 08, 2019	BUY	$8.65 - $14.81 $61,371 - $105,076	7,095 Added 26.46%	33,908 $501,000
Q2 2019 Aug 09, 2019	BUY	$7.1 - $11.62 $5,183 - $8,482	730 Added 2.8%	26,813 $312,000
Q1 2019 May 14, 2019	BUY	$7.95 - $14.07 $120,148 - $212,639	15,113 Added 137.77%	26,083 $282,000
Q3 2018 Nov 13, 2018	BUY	$13.94 - $19.88 $152,921 - $218,083	10,970 New	10,970 $179,000

Others Institutions Holding VRCA

# of Institutions

Shares Held

16.2M

Call Options Held

Put Options Held

View Full List

About Verrica Pharmaceuticals Inc.

Ticker VRCA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,094,100
Market Cap $300M
Description
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, develops and commercializes treatments for people with skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; that has completed Phase II clinical trial for the treatment of external genital warts; and w...

More about VRCA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.

Account

Charles Schwab Investment Management Inc Verrica Pharmaceuticals Inc. Transaction History